Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer

References

• Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Colonna M, Guizard AV, Schvartz C, et al. A time trend analysis of papillary and follicular cancers as a function of tumour size: A study of data from six cancer registries in France (1983–2000). Eur J Cancer. 2007;43:891–900.
   PubMed Web of Science ®Google Scholar
• Deshpande H, Gettinger S, Sosa J. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol. 2008;20:19–24.
   PubMed Web of Science ®Google Scholar
• Hu-Lowe D, Hallin M, Feeley R, et al. Characterization of potency and activity of the VEGF/PDGF receptor tyrosine kinase inhibitor AG013736 [abstract]. Proc Am Assoc Cancer Res. 2002;43:5357.
   Google Scholar
• Cohen E, Rosen L, Vokes E, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708–4713.
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel A, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714–4719.
   PubMed Web of Science ®Google Scholar
• Sprague B, Andersen S, Trentham-Dietz A. Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes Control. 2008;19:585–593.
   PubMed Web of Science ®Google Scholar
• Hodgson N, Button J, Solorzano C. Thyroid cancer: Is the incidence still increasing? Ann Surg Oncol. 2004;11:1093–1097.
   Google Scholar
• Carling T, Udelsman R. Cancer of the endocrine system: Section 2 thyroid tumors. In: De Vita V, Hellman S, Rosenberg S, editors. Cancer principles and practice. 8th Edition. Philadelphia: Lippincott Williams and Wilkins; 2008. p. 1664–1682.
   Google Scholar
• Sosa J and Udelsman R. Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol. 2006;94:701–707.
   PubMed Web of Science ®Google Scholar
• Sherman S. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin N Am. 2008;37:511–524.
   PubMed Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–2899.
   PubMed Web of Science ®Google Scholar
• Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155–2160.
   PubMed Web of Science ®Google Scholar
• Gupta V, Pattaswamy K, Lassoued W, et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma [abstract]. Proc Am Soc Clin Oncol. 2007;25:6019.
   Web of Science ®Google Scholar
• Sherman S, Wirth L, Droz J-P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008; 359:31–42.
   PubMed Web of Science ®Google Scholar
• Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625–627.
   PubMed Web of Science ®Google Scholar
• Rugo H, Herbst R, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;3:5474–5483.
   Google Scholar
• Martin L, Kosloff M, Herbst R, et al. Phase I study of axitinib (AG-013736) in combination with chemotherapy in patients with advanced solid tumors [abstract]. Ann Oncol. 2008;19:472.
   Google Scholar
• Robles R, Burgess R, Infante J, et al. Axitinib (AG-013736; AG) in combination with chemotherapy (CT): A phase 1 study in patients (PTS) with gastrointestinal tumors [abstract]. Ann Oncol. 2008;19:473.
   PubMedGoogle Scholar
• Michael M, Vlahovic G, Khamly K, Pierce K, Guo F, Ozlanski. A Phase Ib study of CP-868,596, a PDGFR inhibitor, in combination with docetaxel (Doc) with or without AG-013736, a VEGF inhibitor [abstract]. Proc Am Soc Clin Oncol. 2008;26:3549.
   Web of Science ®Google Scholar
• Abhyankar V, Sharma S, Trowbridge R, et al. Axitinib (AG-013736) in combination with FOLFOX and bevacizumab (bev) in patients (pts) with advanced solid tumors: A phase 1 study [abstract]. Proc Am Soc Clin Oncol. 2008;26:4112.
   Web of Science ®Google Scholar
• Rini B, Schiller J, Fruehauf J, et al. Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736) [abstract]. Proc Am Soc Clin Oncol. 2008;26:3543.
   PubMed Web of Science ®Google Scholar
• Anon. Clinical Trials with axitinib and thyroid cancer. 2008. Cited 2008 Oct. Available from: http://www.clinicaltrials.gov/
   Google Scholar
• Trask P, Bushmakin A, Cappelleri J, Bycott P, Liau K, Kim S. Health-related quality of life during treatment for renal cell carcinoma: Results from a phase II study of axitinib. Acta Oncol. 2008;47:843–851.
   PubMed Web of Science ®Google Scholar